Italian researchers followed 2,570 people with relapsing-remitting MS who were treated with disease-modifying drugs for up to seven years. Every six months, investigators tracked disease progression, rating physical disability on a scale from 1 to 10. Compared to those whose treatment was delayed, they found early treatment significantly reduced the risk of future disability.
National MS Society invites investigators to apply for expedited funding to quickly explore the lead regarding CCSVI (reported first in November eNews). This lead is based on very small studies. Our medical advisers urge people who have questions to visit our Web site. Treatments based on this hypothesis should be done only in a clinical trial setting. (Pictured right: Dr. Zamboni, CCSVI researcher)
Your year-end gift is more than a tax benefit. Your donation will help provide funds for MS researchers who are pursing an end to multiple sclerosis and will support programs and services for people living with MS and their families.
MS stops people from moving. The National MS Society exists to make sure it doesn’t. We are a collective of passionate individuals, moving together to create a world free of MS. JOIN THE MOVEMENT®
Please do not reply to this email as we are unable to quickly respond to messages sent to this address. To receive information about living with MS, Bike MS or Walk MS — or to contact National MS Society staff in your area — please visit our Web site.
Early and ongoing treatment with an FDA-approved therapy can make a difference for people with multiple sclerosis. Learn about your options by talking to your health care professional and contacting the National MS Society at http://www.nationalmssociety.org/ or 1-800-344-4867.
National Multiple Sclerosis Society | 733 Third Avenue | New York, NY | 10017
This message was sent to . To ensure that you continue to receive our emails, please add us to your address book.